Analysts Weigh Up Benefits Of Big Bayer Restructuring
The investment community has praised Bayer's bosses for a "much-needed shake-up and slimming down of the organisation" as management increases its focus on the core pharmaceuticals business and looks to exit animal health.
You may also be interested in...
Bayer will sell Coppertone sunscreen and Dr. Scholl’s foot care brands to focus on growing its core consumer health brands. Although the plan represents ‘failure” in turning around sales for both brands, it is a ‘sensible’ move, say analysts.
EU approval and coming launch there of Jivi will complement Bayer's two existing Factor VIII treatments, Kogenate and its successor Kovaltry.
Vitrakvi is effective against a wide variety of cancers driven by NTRK fusion. But finding the patients who will benefit will be a challenge, given there are expected to be only around 2,500 to 3,000 new cases in the US and testing for the mutation is uncommon.